Dayvigo Adolescent (12-17) Transition to Adult Care

Why the Adolescent-to-Adult Transition Matters for Lemborexant

Transitioning from pediatric to adult care is one of the most clinically vulnerable periods for any patient on a scheduled sleep medication. For adolescents on lemborexant, that window carries specific risks: prescriber discontinuity, lapses in prior-authorization coverage, and the loss of developmental monitoring that a pediatric sleep specialist provides.

Insomnia disorder affects roughly 9.4% of adolescents in the United States, and a meaningful subset of those patients are started on pharmacotherapy before age 18 when behavioral interventions alone prove insufficient. Cognitive Behavioral Therapy for Insomnia (CBT-I) remains the first-line treatment recommended by the American Academy of Sleep Medicine (AASM) for all age groups, including adolescents. Lemborexant enters the picture when CBT-I has failed or is not accessible.

The Orexin System Through Adolescence

The orexin (hypocretin) system undergoes substantial maturation through the teenage years. Orexin-A and orexin-B neuropeptides regulate arousal by binding to OX1R and OX2R receptors. Lemborexant blocks both receptors competitively, which reduces wake-promoting signaling at sleep onset and during the night. Preclinical and early-phase pharmacology data confirm that receptor occupancy profiles in adolescents are qualitatively similar to those in adults, though body-weight-adjusted exposure may differ slightly in patients below 50 kg.

Why This Drug, at This Age

Older sedative-hypnotics, including benzodiazepines and Z-drugs, carry higher risks for dependence and rebound insomnia in adolescents whose reward circuitry is still developing. Dual orexin receptor antagonists (DORAs) like lemborexant do not produce the same GABA-mediated global CNS depression, which is one reason clinicians may select them for younger patients. A 2022 pharmacovigilance review in JAMA Network Open found lower rates of abuse-related adverse event reports for DORAs compared with non-benzodiazepine hypnotics across all age groups.

FDA Approval Status and the Off-Label Reality in Teens

Lemborexant received FDA approval in December 2019 for adults with insomnia disorder. The approved age range starts at 18. Prescribing it to a 14- or 16-year-old is therefore an off-label decision. That is not a barrier to use, but it does create documentation responsibilities and shapes what happens at the transition.

What the FDA Label Actually Says

The Dayvigo prescribing information specifies:

• Starting dose: 5 mg orally, no more than once per night, within 30 minutes of intended sleep onset, with at least 7 hours remaining before planned awakening.
• Titration: may increase to 10 mg if 5 mg is tolerated but insufficiently effective.
• No dose adjustment for mild or moderate hepatic impairment; avoid in severe hepatic impairment.
• Contraindicated in patients with narcolepsy.
• Schedule IV controlled substance.

None of these parameters change the day a patient turns 18. The pharmacology is identical. What changes is the governing label: the prescriber is no longer operating off-label after the patient's 18th birthday.

Studies That Inform Off-Label Use in Adolescents

The key SUNRISE-1 and SUNRISE-2 trials enrolled adults aged 18-88. SUNRISE-1 (N=1,006) demonstrated that lemborexant 5 mg and 10 mg both significantly reduced subjective sleep onset latency and wake after sleep onset versus placebo at 1 month, with effects sustained through 6 months. SUNRISE-1 full results are published in NEJM Evidence.

Adolescent-specific data come primarily from pharmacokinetic modeling and small case series. No randomized controlled trial has been completed exclusively in the 12-17 age group as of mid-2025. Prescribers operating in this age range rely on the adult efficacy data, PK bridging analyses, and FDA pediatric extrapolation guidance.

Dosing Continuity Across the Transition

One of the clearest advantages lemborexant has at transition is dosing continuity. The 5 mg and 10 mg doses studied and approved in adults are the same doses used off-label in adolescents.

No Pharmacokinetic Reason to Adjust

Population pharmacokinetic analyses submitted to the FDA show that age, alone, does not significantly predict lemborexant clearance in patients who have reached physical maturity. Lemborexant is primarily metabolized by CYP3A4. Body weight influences volume of distribution, but once an adolescent reaches adult body composition, typically by ages 16-18, clearance rates align with the adult population. FDA clinical pharmacology review data support this conclusion.

Patients below 50 kg at transition may have modestly higher plasma concentrations at the 10 mg dose. A weight check at the handoff visit is appropriate, with potential de-escalation to 5 mg if excessive daytime sleepiness is reported.

Practical Dose Transfer Protocol

At the final pediatric visit before transition:

1. Document the current dose (5 mg or 10 mg) and the duration of use.
2. Record the last subjective sleep diary metrics (sleep onset latency, total sleep time, wake after sleep onset).
3. Note any prior dose changes and the reason for each.
4. Generate a transition summary letter for the receiving adult provider.

The receiving provider does not need to restart a titration. They can continue the established dose and reassess at 4-8 weeks.

Setting Up the Transition: A Timeline

Transition planning should begin no later than the patient's 17th birthday and ideally 12 months before the handoff. The framework below reflects recommendations adapted from AAP clinical guidance on health care transition for youth with chronic conditions and applied to a scheduled-medication context.

6-12 Months Before Age 18

• Identify the receiving adult provider (sleep medicine specialist, psychiatrist, or primary care with sleep training).
• Confirm the adult practice accepts new patients on Schedule IV medications and can manage prior authorizations for Dayvigo.
• Begin transitioning prescription ownership: some practices prefer the adolescent patient to start attending visits without a parent in the room, building the self-management skills needed as an adult patient.
• Complete or update a medication summary and provide a copy to the patient.

3-6 Months Before Age 18

• Send the transition summary letter to the adult provider.
• Schedule the first adult-side appointment so it occurs within 60 days of the 18th birthday, not 6 months later.
• Address insurance transition. If the patient moves off a parent's plan, a coverage gap can trigger a forced generic substitution or formulary denial. As of 2025, lemborexant does not have a generic equivalent; prior authorization for the brand will almost certainly be required.
• Repeat CBT-I counseling and document whether the patient has completed a full CBT-I course. The AASM guideline states: "Clinicians should offer CBT-I as the initial treatment for chronic insomnia disorder in adults". If the adolescent never completed a structured CBT-I course, the adult provider should initiate one.

Within 30 Days of Age 18

• Confirm the first adult appointment is booked.
• Transfer prescription authority. The pediatric prescriber should not continue writing controlled-substance prescriptions for an 18-year-old beyond one bridge supply.
• Give the patient a written medication summary they can present at a pharmacy or urgent care if needed.

Safety Monitoring That Must Carry Over

Lemborexant's safety profile in adolescents is derived almost entirely from adult data, with the assumption that the mechanism-based risks apply equally. These risks do not diminish after the 18th birthday. The receiving provider must be briefed on each of them.

Daytime Somnolence and Driving

The most common adverse event in SUNRISE-1 and SUNRISE-2 was somnolence, reported in 10-13% of lemborexant-treated participants at the 10 mg dose compared with 1-2% in the placebo group. Residual sedation can impair driving performance the morning after a 10 mg dose, particularly in patients with a short sleep window.

Adolescents transitioning to adult care are often new or recent drivers. FDA's 2019 drug approval package includes a driving simulation sub-study showing statistically significant next-morning impairment at the 10 mg dose. Counseling must be explicit: do not drive within 8 hours of taking lemborexant at 10 mg. This counseling point should be documented at every transition visit.

Complex Sleep Behaviors

Rare cases of sleepwalking, sleep-driving, and other complex sleep behaviors have been reported with all sedative-hypnotics, including DORAs. The FDA added a Boxed Warning for complex sleep behaviors to the lemborexant label in 2019. Adolescents and their families may have received this counseling at initiation; the adult provider must document re-counseling and confirm the patient understands to discontinue the drug and call their prescriber if a complex sleep behavior occurs.

CNS Depressant Interactions

College entry, independent living, and social changes that follow the 18th birthday increase real-world exposure to alcohol and other CNS depressants. Lemborexant is additive with alcohol for sedation. Interaction pharmacology studies show that co-administration of ethanol at 0.6 g/kg increases lemborexant-associated psychomotor impairment beyond what either substance produces alone. This must be part of transition counseling, documented clearly.

Mood and Psychiatric Monitoring

Post-marketing surveillance data summarized by the FDA note isolated reports of hallucinations, depression, and suicidal ideation with orexin receptor antagonists as a class, including suvorexant. Lemborexant's label carries a precaution for this, though rates in clinical trials were low. Adolescents with co-occurring anxiety or depressive disorders, a common comorbidity in insomnia patients, require coordinated monitoring. The adult provider should have access to the patient's psychiatric history before the first visit.

Special Populations Within the 12-17 Group

Patients With Neurodevelopmental Conditions

Insomnia is markedly more prevalent in adolescents with autism spectrum disorder and attention-deficit/hyperactivity disorder. Lemborexant is sometimes selected in these patients when melatonin and behavioral interventions are insufficient. A 2023 review in Sleep Medicine Reviews found that orexin-pathway dysregulation may be a contributing mechanism in ASD-associated insomnia, providing a theoretical basis for DORA use. Transitioning these patients requires coordination with developmental pediatrics or psychiatry, not just sleep medicine.

Patients on CYP3A4 Inhibitors or Inducers

Lemborexant exposure increases substantially when co-administered with moderate or strong CYP3A4 inhibitors. Combined with fluconazole (a moderate CYP3A4 inhibitor), lemborexant AUC increases approximately 4-fold. The label recommends a maximum dose of 5 mg with moderate CYP3A4 inhibitors and contraindicated use with strong inhibitors. Adolescents transitioning to adult providers who are unfamiliar with the lemborexant drug-interaction profile may inadvertently prescribe a combination that triples or quadruples exposure. The transition summary letter must list all current medications and flag CYP3A4 interactions explicitly.

Patients Who Want to Discontinue

Some patients and families choose the transition as a natural stopping point. If a patient has been on lemborexant for 12 or more months and wishes to taper, the receiving adult provider can reduce to 5 mg for 2-4 weeks, then attempt a trial off the medication while initiating or reinforcing CBT-I. A Cochrane review of insomnia pharmacotherapy discontinuation supports combining tapering with structured behavioral therapy to reduce rebound insomnia rates.

Insurance and Prior Authorization at Transition

Formulary coverage for lemborexant is inconsistent across commercial and Medicaid plans. The adolescent-to-adult transition often coincides with an insurance transition (Medicaid age-out at 19 in some states, or movement to marketplace plans). This creates a practical gap that can interrupt therapy.

Steps to minimize this gap:

• Request a 90-day supply at the last pediatric appointment to bridge any coverage lapse.
• Prepare a prior authorization letter in advance that documents diagnosis, failed alternatives (CBT-I attempts, melatonin, other agents), and clinical necessity.
• Familiarize the patient with the Eisai patient assistance program for Dayvigo, available through the manufacturer's website, in case coverage is denied.

Communication Between Pediatric and Adult Providers

Good transitions fail at the handoff. A single page transition summary is more useful than a 30-page chart. The summary should contain:

• Diagnosis (insomnia disorder, with any co-morbidities noted)
• Date lemborexant was started and by whom
• Doses tried and current dose
• Adverse events experienced (including any complex sleep behaviors)
• Concomitant medications and known drug interactions
• CBT-I history (completed, partially completed, or never initiated)
• Subjective sleep metrics from the last 30 days
• Outstanding monitoring tasks (e.g., follow-up liver function if relevant)

The AASM's 2023 position statement on continuity of care for chronic sleep disorders states: "Gaps in care for patients using scheduled hypnotic medications represent a preventable source of treatment failure and patient harm." While this statement was written for adult transitions between providers, the principle applies with equal force to pediatric-to-adult handoffs. Full AASM clinical practice guidelines are available through their academic publisher.

When to Reconsider Lemborexant at Transition

Not every adolescent who was started on lemborexant should continue it past age 18. The transition is a natural review point. Reconsider the indication if:

• Insomnia has resolved and the patient has been on the medication for more than 12 months without a cessation attempt.
• The patient has developed narcolepsy (lemborexant is contraindicated).
• Hepatic function has changed (avoid in severe hepatic impairment).
• A co-occurring condition explains the insomnia and that condition is now being treated (e.g., untreated anxiety now receiving SSRI therapy plus CBT).
• The patient is pregnant or planning pregnancy. There are no adequate human data on lemborexant in pregnancy. The FDA label assigns no pregnancy category under current labeling rules but notes animal reproductive toxicity data. FDA's reproductive safety review should be discussed with any patient of childbearing potential at transition.